Emma Guttman-Yassky, MD, PhD is an Associate Professor of Dermatology & Immunology at the Icahn School of Medicine at Mount Sinai in New York. She is the Director of the center for excellence in eczema and the occupational dermatitis clinic and director of the laboratory for inflammatory skin diseases.
S
he earned her M.D. degree from Sackler School of Medicine at the Tel-Aviv University, and a Ph.D. degree from the Bar-Ilan University, Israel. After obtaining her Israeli Board certification in dermatology at Rambam Medical Center/Technion, Israel, Dr. Guttman moved to the U.S. to pursue a two-year postdoctoral fellowship at The Rockefeller University in the Laboratory for Investigative Dermatology. Upon completion of her fellowship, she became board-certified by the American Board of Dermatology followiing her second dermatology residency training at the Weill-Cornell Medical College in New York. Dr. Guttman’s major clinical and research focus is atopic and contact dermatitis.
Her research made paradigm-shifting discoveries on the immunologic basis of atopic dermatitis (AD) in humans, enriching the understanding of the pathophysiology of this common disorder and opening the door to new therapeutics. Dr. Guttman has developed the only comprehensive molecular maps of AD, defining skin differentiation and immune-circuits characterizing this disease. She has established the reversibility of the AD phenotype and defined a series of disease and response biomarkers that are now accelerating the testing of novel immune, pathway-specific drugs in this disease.
Dr Guttman was recently (2015) elected as a member to the American Society for Clinical Investigation (ASCI), as well as the American Dermatological Society (ADA), and is the recipient of the Young Investigator Award (2011) from the AAD, the Dermatology Foundation’s Physician-Scientist Career Development Award, the Fisher award of the American Contact Dermatitis Society. Her breakthrough studies in eczema were featured in important journals and media channels.
*Learn more: Visit ClinicalTrials.gov trial # NCT02561585 for more details.